Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Tukysa (tucatinib by Quarter
Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — Worldwide revenues ($M) ($M)
Pfizer Tukysa (tucatinib: $138M in Q2 2026, up 4.5% from a year earlier. That is the highest of the 14 quarters on record here.
Where the Q2 2026 figure comes from
“|| Tukysa | 138 | 132 | 5% | 4% | 96 | 107 | (11%) | 42 | 24 | 73% | 67%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up tukysa (tucatinib
- Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — U.S. revenues ($M)96 · Q2 2026
- Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — International revenues ($M)42 · Q2 2026
- Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — Worldwide reported YoY (%)5.0% · Q2 2026
- Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — Worldwide operational (constant-currency) YoY (%)4.0% · Q2 2026
Cite this data
StockData. (2026). Pfizer Tukysa (tucatinib ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/tukysa-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.